NCT04430933 2021-08-18
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
NextCure, Inc.
Phase 1/2 Withdrawn
NextCure, Inc.
Eli Lilly and Company
iOMEDICO AG
The University of Texas Health Science Center, Houston
AmpliMed Corporation